17:35 , Nov 29, 2017 |  BioCentury  |  Emerging Company Profile

Gluten-free gut

PvP Biologics Inc. is developing an oral enzyme therapy for celiac disease to break down gluten in the stomach with more specificity than a competing enzyme cocktail. The company’s KumaMax, a synthetic peptidase, should prevent...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

Cour Pharmaceutical, Takeda deal

Cour partnered with Takeda to develop and commercialize therapies for celiac disease and other gastrointestinal diseases using Cour’s Tolerizing Immune Modifying nanoParticle (TIMP) platform. TIMP therapy consists of encapsulated antigenic proteins and a polymer. The...
08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

Ig-plex Celiac DGP Panel regulatory update

FDA granted 510(k) clearance to SQI Diagnostics’ Ig-plex Celiac DGP Panel as an aid in diagnosing celiac disease. The immunofluorescent assay runs on the sqid-X system and provides semi-quantitative determination of IgG and IgA antibodies...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

BL-7010: Phase I/II data

Data from the first part of a double-blind, placebo-controlled, Finnish Phase I/II trial in up to 32 well-controlled patients with celiac disease showed that all 6 single ascending doses of oral BL-7010 were well tolerated...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

BL-7010: Phase I/II started

BioLineRx began a double-blind, placebo-controlled, Finnish Phase I/II trial to evaluate single and multiple ascending-doses of oral BL-7010 in up to 32 well-controlled patients with celiac disease. BioLineRx also plans to begin an efficacy study...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

BL-7010: Phase I/II start

By year end, BioLineRx will begin a double-blind, placebo-controlled, Finnish Phase I/II trial to evaluate single and multiple ascending-doses of oral BL-7010 in up to 32 well-controlled patients with celiac disease. BioLineRx also plans to...
07:00 , Mar 26, 2012 |  BioCentury  |  Emerging Company Profile

ImmusanT: Having their cake

ImmusanT Inc. is developing what could be the first treatment for celiac disease that allows patients to eat a normal diet. The company's Nexvax2 vaccine seeks to reprogram CD4+ T cells to induce gluten tolerance. The...
08:00 , Feb 27, 2012 |  BC Week In Review  |  Clinical News

BioLineRx preclinical data

In gluten-sensitized mice, oral BL-7010 attenuated immune responses triggered by gluten and prevented gluten-induced pathological damage to the small intestine vs. untreated controls. Additionally, BL-7010 reduced digestion of wheat gluten and barley hordein in...
08:00 , Mar 3, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Mouse model of early celiac disease A mouse model of celiac disease could aid...
07:00 , Sep 23, 2010 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Engineered wheat for celiac disease A cell culture study suggests that a genetically engineered strain of wheat could be...